Oncology
ASCO 2023

ASCO 2023 – Gregory Lubiniecki

With its blockbuster checkpoint inhibitor Keytruda, Merck has been a star of the show at many ASCO conferences in recent years.

R&D
Stephen Head, senior director, Patient Partnerships at Astellas Pharma Europe

How can we achieve a world without disease?

Delivering the vision of a world where disease is no longer an insurmountable burden for patients and healthcare professionals would be a phenomenal achievement in the history of medicine.

Sales & Marketing

Digital

Market Access

Editor's Picks

  1. Axsome breaks new ground in Alzheimer's with Auvelity OK
  2. Merck partners Remepy in PDURS-focused alliance
  3. Teva makes its first M&A play in years, buying Emalex
  4. UK study finds clue to rising cancer rates in younger people
  5. Boehringer/Zealand dual-acting drug causes 16.6% weight loss

Newsletters and Deep Dive
digital magazine

Oncology

more

Patients

Patients
Anatomical graphic concept of a liver in 3D

Rewriting the MASLD playbook

Effective care now requires identifying metabolic risks early and addressing the broader factors driving liver damage.

more

R&D

more